News Daily News No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits Michael O'Riordan July 14, 2025
News Daily News Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI Michael O'Riordan April 22, 2025
News Conference News ACC 2024 Need a Statin for Primary Prevention? There’s an App for That Michael O'Riordan April 10, 2024
News Conference News ACC 2023 Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes Michael O'Riordan March 04, 2023
News Daily News Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees Michael O'Riordan January 05, 2023
News Daily News Genetic Study Hints at Cognitive Impact of Statins, but Experts Urge Caution Michael O'Riordan August 11, 2022
News Conference News ACC 2022 APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study Michael O'Riordan April 03, 2022
News Daily News Could an App Replace Statin Prescribing by Doctors? Michael O'Riordan September 08, 2021
News Conference News AHA 2020 Fish Oil Tanks in STRENGTH, Making Waves for REDUCE-IT Todd Neale November 15, 2020
News Daily News Higher Risk of Intracranial Hemorrhage With Aspirin in Primary Prevention Michael O'Riordan May 20, 2019
News Conference News AHA 2018 REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides Todd Neale November 10, 2018
News Daily News FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen Michael O'Riordan April 25, 2018
News Daily News FDA Advisors Take Fresh Look at Celecoxib Safety as PRECISION Aspirin Analysis Unveiled Michael O'Riordan April 24, 2018
News Features COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict Todd Neale September 15, 2017
News Daily News Staying on Statins After an Adverse Event Lowers Risks of Death, MI or Stroke Michael O'Riordan July 25, 2017
News Daily News Top-Line REVEAL Results Support Efficacy of CETP Inhibition, but Questions Abound Todd Neale June 27, 2017
News Features How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts Michael O'Riordan May 23, 2017
News Conference News ACC 2017 FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo Michael O'Riordan March 17, 2017
News Daily News Evolocumab Modifies IVUS-Detected Coronary Atherosclerosis: Topline Results From GLAGOV Michael O'Riordan September 20, 2016